Background. Phase 3 trials evaluating direct-acting antivirals (DAA) consistently report high sustained virologic responses (SVR). The strict eligibility criteria applied to these studies may affect the reproducibility in clinical practice. It has been demonstrated that drug use generally does not affect SVR. This retrospective cohort study sought to estimate the proportion of patients followed in a tertiary addiction clinic that would meet eligibility criteria for clinical trials, if drug use was not considered as a rejection criteria.
Methods. The sample population consists of patients with active HCV genotypes (GT) 1-3, seen at the clinic between 01/2013 and 09/2015. Information from clinical charts was retrieved to examine how participants would meet the eligibility criteria of 14 studies. Individual patient's data were compared with the studies' eligibility criteria.
Results. A total of 234 patients met the inclusion criteria (GT 1: 58.1%; GT 2: 8.5%, GT 3: 34.2%; experienced: 16.2%; cirrhotic: 14.5%) and 53% (124/234) of patients could have been included in at least one study. Table shows individual study results. The most inclusive study was COSMOS (31/49; 63%). The most frequent exclusion criteria were the presence of significant diseases (cardiac, pulmonary, hepatic, porphyria or other), contraindicated medication and haemoglobin level.
Conclusion. Even without considering drug use, only half of the patients of the addiction clinic would have been eligible for at least one study. This under-representation stems from strict eligibility criteria that promote a healthier population. Our study suggests that the DAA might prove less effective when administered to infected populations followed in specialized clinics for drug. Background. The Victorian Infectious Diseases Service currently provides telehealth care for rural and regional patients with hepatitis C. From March 2016 direct acting antiviral therapy (DAA) for Hepatitis C has been subsidised for all Australian adults with Hepatitis C. The wide geographic distribution of Australia's population means patients have to travel considerable distances to access specialist care. The increasing availability of web-based videoconferencing platforms have provided unprecedented capacity to manage patients remotely. The primary aim of this study is to determine whether telehealth delivered hepatitis C management achieves virological outcomes comparable to that achieved in randomised clinical trials.
Methods. The study is part of a quality audit of the hepatitis and outreach service. Measured outcomes were; (i) proportion of patients achieving a sustained virological response (SVR); (ii) failure to attend rate (FTA); (iii) frequency of technical difficulties; (iv) patient travel kilometres saved through not attending clinic in person; (v) Reduced carbon production due to reduced travel; and (vi) Consultation duration time.
Results. In 1 year from March 1 , 2016, 58 patients have been commenced on Hepatitis C treatment and managed either partially or completely via telehealth. Of those who have so far completed therapy (29 patients) an SVR rate of 97% has been achieved. Expected SVR genotype 1 (>95%); genotype 3 (>85%). The average travel avoided for each telehealth consultation was 616km and each patient had a median of two telehealth consultations. Technical difficulties occurred in less than 10% of consultations with FTA of 17%. Consult duration averaged 15 minutes or less.
Conclusion. Background. Despite increased focus on understanding the HCV cascade of care, data is limited in the DAA era, particularly in an urban community health setting. We aimed to study the HCV cascade of care at an urban community health center in the DAA era and to identify barriers to linkage to care, referral and treatment of HCV.
Methods. We performed a retrospective review of patients with a positive HCV antibody and a visit at Dimock Community Health Center from October 31, 2014 to November 1, 2016. Data were abstracted from medical records for demographic details, medical and psychiatric comorbidities, substance abuse information and HCV specific characteristics such as genotype, HIV/Hepatitis B co-infection, and fibrosis scoring. Data were also abstracted for 52 patients actively engaged in HCV care with prior positive testing or who tested positive during the study period. Descriptive statistics, pair wise comparisons with Chi -Square, Fischer's exact and T-test were used to identify characteristics associated with referral and treatment of HCV infection.
Results. 107 patients with positive HCV antibody were identified. HCV RNA was sent for 87 (81 %) and was detectable in 53 of 87 (61 %). Forty-two (48 %) were referred to care and 31 (36 %) were seen by infectious disease or hepatology. Fifteen (17.2 %) were approved for treatment. Age > 35, stable housing, and the absence of anxiety and hypertension were significantly associated with referral for HCV treatment. Of the patients who were HCV RNA positive, 32% were not referred for HCV treatment; the main reasons for non-referral were loss to follow-up and co-morbidities. Of the 52 patients actively engaged in HCV care, 49 had detectable HCV RNA. Twenty-eight (47 %) started treatment, and 10 (20 %) are awaiting insurance approval. Nineteen (68 %) patients have completed treatment and 9 remain on treatment.
Conclusion. In this community based study, loss to follow-up and comorbidities led to non-engagement in care for 31% of patients with positive HCV RNA. When engaged in care, treatment success rates were comparable to other real-world studies. Our study suggests that specific interventions at different points in care may overcome loss from, or non-engagement in care. Opportunities exist for patient and provider education targeting high-risk populations at opioid substitution clinics and needle exchanges.
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No reported disclosures. (born between 1945 and 1965) . However, only 50% of HCV-positive individuals are aware they are infected, and far fewer attend an outpatient appointment and are initiated on treatment (Linkage to Care: LTC). The aim of this study is to assess the factors affecting LTC among HCV positives in a suburban tertiary medical center on Long Island, NY.
Barriers to Successful Linkage to
Methods. A retrospective chart review was performed on all patients with ICD-9 or 10 diagnostic codes for HCV positive antibody from January 2016 to March 2017 at Stony Brook University Hospital. Data were collected for HCV RNA, LTC, demographics, insurance and employment status, psychiatric diagnosis, comorbid medical conditions, substance use disorder, injection drug use, liver and kidney function, level of fibrosis.
Results. A total of 155 cases (61.9% male; mean age 53.9 years) had a positive HCV antibody, 110 (71%) had a follow-up HCV RNA test and 35.1% were LTC. The comorbidities present in this cohort were psychiatric disease (54.9%), cirrhosis (22.6%), HBV infection (14.1%) and HIV (8.5%). In the univariate analysis, new inpatient HCV diagnosis (OR = 0.09, 95% CI: 0.02-0.36, P = 0.001), employment (OR = 3, 95% CI: 1.01-8.95, P = 0.049) and history of substance use disorder (OR = 0.38, 95% CI: 0.15-0.96, P = 0.043) were associated with LTC. In the logistic regression analysis, inpatient HCV diagnosis was negatively correlated with LTC (OR: 0.03, 95% CI: 0.002-0.41, P = 0.009). Two hot spots of HCV infection were identified in south central Suffolk County.
Conclusion. In this population, new inpatient HCV diagnosis and history of substance use disorder were less likely to have LTC, whereas those employed were more likely to have LTC. Innovative interventions in the inpatient setting may be beneficial for newly diagnosed HCV cases to improve LTC after discharge.
Disclosures. All authors: No reported disclosures. October 5, 2017: 12:30 PM Background. The newly introduced direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection have substantially higher cure rates and less side effects compared with previous regimens. However, in order to achieve optimal patient engagement in HCV treatment, it's highly imperative to develop comprehensive HCV treatment programs which provide optimal services that help navigate patients through a challenging healthcare system.
Implementation of a Comprehensive Hepatitis C Virus (HCV) Treatment
Methods. In 2014, a comprehensive HCV treatment program employing a multidisciplinary team service was created at our Ryan White sponsored clinic in Metro-Detroit. The team which included infectious disease physicians, nurse practitioners and social
